An IGF-1 test only means something once it's read against your age-adjusted reference range, not the flat cutoff printed at the bottom of the lab report — a 28-year-old and a 55-year-old can post the same raw number and land on opposite ends of normal. The single value that actually predicts whether peptide therapy will help you is the trend across two or three draws, not one number, because oral estrogen, recent illness, and liver function can swing IGF-1 without touching your real growth hormone axis. Read the result with a clinician before you order Sermorelin, Ipamorelin, or CJC-1295 — not after.
TL;DR
- IGF-1 must be read against your age-adjusted range, not a flat lab cutoff, before starting peptide therapy in 2026.
- A result below the age-adjusted range is the strongest candidate profile for growth hormone secretagogue peptides like Sermorelin or Ipamorelin/CJC-1295.
- IGF-1 above the reference range pauses peptide therapy and triggers an endocrine workup for excess GH signaling.
- Oral estrogen, liver disease, recent illness, and assay differences can swing IGF-1 without changing your actual GH axis.
- Retest IGF-1 roughly every 90 days to confirm the trend, not just the starting number.
- IGF-1 only means something read against your age-adjusted range, not a flat lab cutoff.
- The trend across two or three draws predicts peptide response better than any single number.
- Below-range IGF-1 with matching symptoms is the strongest case for Sermorelin or Ipamorelin/CJC-1295.
- Above-range IGF-1 pauses peptide therapy and triggers an endocrine workup, not a prescription.
- Oral estrogen, liver function, illness, nutrition, age, and assay platform can all swing the number without changing your real GH axis.
- Retest IGF-1 roughly every 90 days once peptide therapy starts to confirm the protocol is working.
Why this matters
Growth hormone itself pulses in short bursts and clears from blood within minutes, so testing it directly is close to useless. IGF-1 is the stable, liver-produced proxy clinicians actually use, because it holds steady for days and reflects your average GH exposure instead of a random pulse. The fix starts with knowing which labs to run before starting hormone therapy, IGF-1 included.
Misreading it is easy in both directions. A patient with a mid-range IGF-1 taken during a head cold, or three weeks into an oral estrogen prescription, can look like a poor candidate for growth hormone secretagogue peptide therapy when the real issue is the test conditions, not the growth hormone axis. The reverse happens too — a genuinely low IGF-1 gets waved off as "probably just aging" without ever checking whether it's actually below the age-adjusted range.
Growth hormone, thyroid, cortisol, and metabolic markers move together as one system. Within Cardiometabolic Optimization, IGF-1 is treated as one piece of that system, not a number that gets interpreted alone in 2026.
The single value that actually predicts whether peptide therapy will help you is the trend across two or three draws, not one number.
How to interpret an IGF-1 test before starting peptide therapy
Interpretation comes down to three things: where the number falls against your age-adjusted range, what else is happening in your body at the time of the draw, and whether it's a single data point or part of a tracked trend.
IGF-1 result vs. age-adjusted range
Peptide therapy implication by range
| IGF-1 result vs. age-adjusted range | What it usually suggests | Peptide therapy implication |
|---|---|---|
| Below the range | Reduced GH pulsatility or possible deficiency | Strongest profile for growth hormone secretagogue peptides |
| Lower half of the range | Age-typical decline, no clear deficiency | Candidate if symptoms (poor recovery, low lean mass, poor sleep) support it |
| Upper half of the range | Normal GH axis function | Peptide therapy rarely indicated on labs alone |
| Above the range | Excess GH signaling | Therapy paused, endocrine workup ordered |
Below-range IGF-1 paired with matching symptoms is the profile GoodLife Health's clinicians see respond best to Sermorelin or Ipamorelin/CJC-1295 — the two most commonly discussed growth hormone secretagogue peptides. Above-range IGF-1 is never a peptide therapy start point; it's a referral point.
!Three IGF-1 range categories and their peptide therapy implications
Where the number falls decides whether peptide therapy starts, waits, or gets referred out.
Low IGF-1: the strongest case for growth hormone peptide therapy
An IGF-1 result below your age-adjusted range is the clearest signal that growth hormone secretagogue peptide therapy is worth discussing. In patients with a documented pituitary or hypothalamic condition, the Endocrine Society's clinical guideline for adult growth hormone deficiency uses an IGF-1 standard deviation score below -2 as one diagnostic marker — a formal way of saying the number isn't just low, it's statistically abnormal for the age group.
Sermorelin and Ipamorelin/CJC-1295 work by prompting the pituitary to release more of its own growth hormone, which raises IGF-1 over weeks, not overnight. Sermorelin: best for a milder, single-peptide starting protocol. Ipamorelin/CJC-1295: best for a stronger, more sustained GH pulse once labs support it. Neither is a direct IGF-1 injection — there's no such product for this purpose, so the peptide's job is to raise your own production, and the retest confirms whether it worked.
The catch: a low number without matching symptoms — poor recovery, declining lean mass, low sleep quality — isn't automatically a prescription. Labs guide the conversation; they don't replace it.
IGF-1 within the age-adjusted range: what it means
A mid-range IGF-1 doesn't rule out peptide therapy, but it shifts the conversation from "deficiency" to "optimization." Patients in the lower half of a normal range who report poor recovery, flat sleep, or stalled body composition changes despite consistent training and diet still get evaluated — the number just carries less weight on its own.
This is where the rest of the panel matters more than IGF-1 in isolation. Thyroid function, testosterone, cortisol pattern, and inflammatory markers like hs-CRP all interact with the growth hormone axis, and a clinician reading IGF-1 without that context is reading one page of a longer chart. A mid-range result paired with a genuinely disrupted metabolic picture can still justify a peptide protocol; a mid-range result with a clean panel usually doesn't.
High IGF-1: why peptide therapy gets paused
An IGF-1 result above the age-adjusted range isn't a peptide therapy candidacy question — it's a referral. Elevated IGF-1 can signal excess growth hormone signaling, and while the most severe cause (acromegaly) is rare, ruling it out comes before any prescription conversation, not after.
High IGF-1 is always a pause-and-refer result, never a peptide therapy start point. A clinician confirming an above-range result orders a repeat draw, checks for symptoms like joint swelling or jaw and hand growth, and coordinates with endocrinology if the pattern holds.
What your clinician checks alongside IGF-1
IGF-1 doesn't get read alone, and neither should the peptide it might justify. Different peptides act through different mechanisms, and only some of them move IGF-1 at all — mixing them up leads to the wrong test being used to judge the wrong drug.
Peptide mechanisms and best-fit use
How each option relates to IGF-1
| Peptide | Mechanism | Best for |
|---|---|---|
| Sermorelin | GHRH analog, prompts the pituitary to release its own GH | A milder single-peptide starting protocol |
| Ipamorelin/CJC-1295 | Combined GH secretagogue, stronger and more sustained GH pulse | Patients wanting a stronger protocol once labs support it |
| BPC-157 | Tissue-repair peptide, not GH-axis driven | Recovery support — candidacy isn't judged by IGF-1 at all |
Sermorelin brings a gentler onset with a slower IGF-1 rise. Ipamorelin/CJC-1295 moves IGF-1 faster but typically involves more frequent injections. BPC-157 doesn't touch IGF-1 in either direction, so it's evaluated on an entirely different basis — this test has nothing to say about it.
How IGF-1 testing works inside a Biomarker Audit
IGF-1 is a fasting, morning blood draw — not because levels swing wildly through the day, but because fasting keeps recent food intake and insulin fluctuation from muddying the rest of the panel it's usually drawn alongside. Results run through the Beluga Health lab network report an age-adjusted range specific to that assay, which is why comparing your number to a range you found online is a mistake — different immunoassay platforms report different absolute values for the same blood sample.
A single draw answers where you stand today. A quarterly Biomarker Audit answers whether a peptide protocol is actually working, which is the more useful question once therapy has already started. Retesting on a fixed 90-day cadence, rather than whenever it's convenient, is what turns one lab value into a trend a clinician can act on.
Why IGF-1 results vary
The same person can post meaningfully different IGF-1 numbers on two separate draws without any real change in growth hormone status. Before treating one result as final, rule out:
- Oral estrogen use — oral (not transdermal) estrogen lowers hepatic IGF-1 production through a first-pass liver effect, independent of GH secretion.
- Liver function — IGF-1 is made in the liver, so impaired liver function can suppress the number regardless of pituitary output.
- Recent illness or acute stress — infections, surgery, and severe caloric restriction all blunt IGF-1 temporarily.
- Nutritional status — inadequate protein intake or a large recent calorie deficit lowers IGF-1 independent of the GH axis.
- Age and pubertal stage — reference ranges shift meaningfully by age; the same raw number can be normal at 60 and low at 30.
- Assay differences — different immunoassay platforms report different absolute IGF-1 values for the same blood sample, which is why the range on your report matters more than a number seen elsewhere.
Related questions about IGF-1 and peptide therapy
Is one IGF-1 test enough to start peptide therapy?
No — one IGF-1 test is a starting point, not a decision. A single value below the age-adjusted range, combined with matching symptoms and the rest of the hormone panel, is what actually supports a peptide therapy recommendation; a lab value with no clinical context is just a number on a page.
How often should IGF-1 be rechecked once peptide therapy starts?
IGF-1 should be rechecked roughly every 90 days once peptide therapy starts, which lines up with a quarterly Biomarker Audit cadence and the same approach used to track hormone levels over time. Retesting on that schedule is how a clinician confirms the protocol raised your own GH output rather than assuming it worked.
Can high IGF-1 disqualify you from peptide therapy?
Yes — an IGF-1 result above the age-adjusted range disqualifies a patient from growth hormone secretagogue peptide therapy until an endocrine workup rules out excess GH signaling. Starting a peptide that raises GH output further in that scenario moves in the wrong direction.
What if IGF-1 is normal but symptoms still suggest low growth hormone?
A normal IGF-1 with persistent symptoms — poor recovery, low lean mass, disrupted sleep — doesn't close the conversation, it widens it. A clinician looks at thyroid, testosterone, and cortisol patterns alongside IGF-1, because a single normal marker in an otherwise disrupted system doesn't mean the system is fine.
FAQ
What is IGF-1 and why is it tested before peptide therapy?
IGF-1 (insulin-like growth factor 1) is a liver-produced hormone that serves as a stable proxy for growth hormone output, since GH itself pulses and clears from blood within minutes. Clinicians test it before peptide therapy because it shows whether the GH axis has room to respond to a growth hormone secretagogue like Sermorelin or Ipamorelin/CJC-1295.
What counts as a normal IGF-1 level for adults?
Normal IGF-1 is defined by an age-adjusted reference range printed on the lab report, not a single universal number, because IGF-1 naturally declines with age. The same raw value can be normal for a 55-year-old and low for a 30-year-old, which is why the range matters more than the raw number.
Can low IGF-1 alone justify starting peptide therapy?
Low IGF-1 alone is a strong signal but not the full picture — a clinician also checks symptoms like poor recovery, declining lean mass, or disrupted sleep before recommending growth hormone secretagogue peptide therapy. Labs guide the decision; they don't make it in isolation.
Does high IGF-1 always mean acromegaly?
No — high IGF-1 doesn't always mean acromegaly, but it does always warrant a repeat draw and an endocrine workup before ruling it out. Acromegaly is the most serious cause of elevated IGF-1, though far from the only possible explanation.
How does oral estrogen affect IGF-1 test results?
Oral estrogen lowers IGF-1 through a first-pass effect on the liver, where IGF-1 is produced, independent of actual growth hormone secretion. Transdermal estrogen doesn't carry the same effect, which is why route of administration matters when interpreting the result.
Is Sermorelin the same thing as an IGF-1 injection?
No — Sermorelin is a growth hormone-releasing hormone analog that prompts the pituitary to produce more of its own growth hormone, which then raises IGF-1 over several weeks. There is no direct IGF-1 injection used for this purpose; the peptide works upstream of the number.
How often should IGF-1 be retested during peptide therapy?
IGF-1 should be retested roughly every 90 days during peptide therapy, matching a quarterly lab cadence, to confirm the protocol is raising your own growth hormone output. A single follow-up test a few weeks in is too early to judge response.
Can a mid-range IGF-1 still support a peptide therapy protocol?
Yes — a mid-range IGF-1 paired with a disrupted metabolic panel, such as low testosterone, high hs-CRP, or poor thyroid markers, can still support a peptide therapy conversation, even without a below-range number. The rest of the hormone panel carries real weight when IGF-1 alone is ambiguous.
One last thing
The number people fixate on — the single IGF-1 result — is the least useful piece of the picture on its own. The trend across two or three draws, read against your age-adjusted range and cross-checked against thyroid, testosterone, and inflammatory markers, is what actually separates a real growth hormone deficiency from a number that dipped because of a cold, a new estrogen prescription, or a rough training block.
Physicians licensed in all 50 states, working under GoodLife Health's clinical protocols, read IGF-1 that way by default — as one data point inside a quarterly Biomarker Audit, not a one-off verdict. If a peptide therapy recommendation ever comes from a single lab value with no symptom check and no retest plan, that's the part worth questioning before the prescription, not after.
Related guides
- Ipamorelin and CJC-1295 therapy for recovery and anti-aging
- Peptide therapy for recovery and metabolic health
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/